| General Information | |
|---|---|
| ZINC ID | ZINC000014975728 |
| Molecular Weight (Da) | 453 |
| SMILES | Cc1c(C(=O)NN2CCCCC2)nn(-c2c(Cl)cc(Cl)cc2Cl)c1-n1cccc1 |
| Molecular Formula | C20Cl3N5O1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 115.634 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| LogP | 5.433 |
| Activity (Ki) in nM | 1819.7 |
| Polar Surface Area (PSA) | 55.09 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.90883207 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 16 |
| Fraction csp3 | 0.3 |
| Ilogp | 3.47 |
| Xlogp3 | 5.56 |
| Wlogp | 4.68 |
| Mlogp | 4.56 |
| Silicos-it log p | 3.54 |
| Consensus log p | 4.36 |
| Esol log s | -6.23 |
| Esol solubility (mg/ml) | 0.000268 |
| Esol solubility (mol/l) | 0.00000059 |
| Esol class | Poorly sol |
| Ali log s | -6.48 |
| Ali solubility (mg/ml) | 0.000151 |
| Ali solubility (mol/l) | 0.00000033 |
| Ali class | Poorly sol |
| Silicos-it logsw | -6.66 |
| Silicos-it solubility (mg/ml) | 0.0000986 |
| Silicos-it solubility (mol/l) | 0.00000021 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.11 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.34 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.496 |
| Logd | 4.057 |
| Logp | 4.312 |
| F (20%) | 0.001 |
| F (30%) | 0.003 |
| Mdck | - |
| Ppb | 99.08% |
| Vdss | 0.884 |
| Fu | 1.56% |
| Cyp1a2-inh | 0.229 |
| Cyp1a2-sub | 0.833 |
| Cyp2c19-inh | 0.891 |
| Cyp2c19-sub | 0.848 |
| Cl | 4.178 |
| T12 | 0.14 |
| H-ht | 0.41 |
| Dili | 0.966 |
| Roa | 0.14 |
| Fdamdd | 0.807 |
| Skinsen | 0.297 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.382 |
| Bcf | 2.071 |
| Igc50 | 4.053 |
| Lc50 | 5.43 |
| Lc50dm | 4.516 |
| Nr-ar | 0.015 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.955 |
| Nr-aromatase | 0.973 |
| Nr-er | 0.624 |
| Nr-er-lbd | 0.025 |
| Nr-ppar-gamma | 0.487 |
| Sr-are | 0.888 |
| Sr-atad5 | 0.099 |
| Sr-hse | 0.43 |
| Sr-mmp | 0.911 |
| Sr-p53 | 0.922 |
| Vol | 408.566 |
| Dense | 1.104 |
| Flex | 0.217 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.602 |
| Synth | 2.887 |
| Fsp3 | 0.3 |
| Mce-18 | 54.846 |
| Natural product-likeness | -1.492 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |